Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia

BACKGROUND: Benign prostatic hyperplasia (BPH) refers to non‐malignant enlargement of the prostate gland that may cause bothersome lower urinary tract symptoms (LUTS). Alpha‐blockers (ABs) and 5‐alpha reductase inhibitors (5‐ARIs) are the mainstay of medical treatment. Recently, phosphodiesterase in...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cochrane Database Syst Rev
Egile Nagusiak: Pattanaik, Smita, Mavuduru, Ravimohan S, Panda, Arabind, Mathew, Joseph L, Agarwal, Mayank M, Hwang, Eu Chang, Lyon, Jennifer A, Singh, Shrawan K, Mandal, Arup K
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley & Sons, Ltd 2018
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6517182/
https://ncbi.nlm.nih.gov/pubmed/30480763
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD010060.pub2
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak